https://www.mangaloremirror.com/ocugen-inc-announces-u-s-fda-clearance-of-ind-amendment-to-initiate-ocu400-phase-3-clinical-trial-first-gene-therapy-to-enter-phase-3-with-a-broad-retinitis-pigmentosa-indication/